Latest Commercialisation News

Castile Resources has added critical mineral bismuth as a by-product to its Rover 1 Bankable Feasibility Study, leveraging a dramatic price surge driven by Chinese export restrictions.

Blue Star Helium has commenced drilling the Jackson 2 well at its Galactica helium project in Colorado, marking a key step in its ongoing development program. The well is progressing towards the Lyons Formation target with plans for flow testing and production tie-in.

First Graphene Limited reported a successful A$2.4 million capital raise alongside promising progress in its PureGRAPH-CEM product trials in the UK and South Africa, while securing key patents and expanding distribution across Asia and South America.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Elevate Uranium Ltd reports steady progress on its U-pgrade demonstration plant and ongoing exploration drilling at Koppies and Marenica projects, alongside a 12% resource increase at the Bigrlyi Joint Venture and the appointment of a new chairman.

Orbital Corporation Ltd reported a positive operating cash flow of $0.7 million for Q1 2025, supported by a solid order book and ongoing development of a new larger capacity engine prototype.

Opyl Limited reports strong progress in AI-driven clinical trial optimisation with active commercial initiatives, strategic partnerships, and a planned capital raise to support growth amid tight cash reserves.

SportsHero Limited has made significant strides in commercialising its iGV Family Game Pass, securing key partnerships with major Southeast Asian telecom operators and expanding its market footprint to the Philippines.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Andromeda Metals has entered exclusive negotiations for a $75 million debt facility to fund the Stage 1A+ development of its Great White Project, alongside operational progress and exploration drilling.

Zelira Therapeutics has enhanced its financial flexibility through a $1.15 million R&D tax refund and a $1 million At-the-Market equity facility, while progressing FDA trial preparations for its HOPE® 1 autism treatment.